

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

### Molnupiravir phase 3 trial, oral famotidine, Novavax clinical trial, future pandemic preparedness, antibody evasion of Omicron sublineages

#### Peer reviewed journals featured:

- A systematic review on tracheostomy timing and outcomes in ventilated COVID-19 patients [here](#)
- Randomised controlled trials of:
  - Molnupiravir for oral treatment of COVID-19 in non-hospitalised patients [here](#) and associated editorial [here](#)
  - Oral famotidine versus placebo in COVID-19 outpatients [here](#)
  - Single dose of Johnson & Johnson (Janssen) vaccine [here](#)
  - The efficacy and safety of Novavax vaccine in adults in the US and Mexico [here](#)
  - High-titre methylene blue-treated convalescent plasma as an early treatment [here](#)
- Observational studies on:
  - Comirnaty (Pfizer) vaccination during pregnancy and associations with neonatal and early infant outcomes [here](#)
  - Viral dynamics and viral variants in the Spikevax (Moderna) phase 3 COVE trial [here](#)
  - Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, Comirnaty (Pfizer), Vaxzevria (AstraZeneca), and a booster dose [here](#)
- A modelling study on the impact of vaccine hesitancy in prolonging the need for non-pharmaceutical interventions to control COVID-19 [here](#)
- Editorials on:
  - Future pandemic preparedness [here](#)
  - Transitioning to endemicity with COVID-19 research [here](#)
- Commentary on life after the COVID-19 pandemic [here](#)

#### Letters and correspondence discussed:

- Protection against the Omicron variant from previous SARS-CoV-2 infection [here](#)
- Effectiveness of homologous or heterologous COVID-19 boosters in US veterans [here](#)
- Analysis of vaccination rates and new COVID-19 infections by US County [here](#)
- Primary care physicians per capita and COVID-19 vaccination rates in US counties [here](#)
- Neutralising Delta and Omicron variants by convalescent plasma and SARS-CoV-2 hyperimmune intravenous human immunoglobulins for COVID-19 treatment [here](#)

## Pre-peer review articles featured:

- Antibody evasion properties of Omicron sublineages (including BA.2) [here](#)
- Trajectories of neurological recovery 12 months after COVID-19 hospitalisation [here](#)
- Symptoms and severity in patients hospitalised with Delta variant infection [here](#)
- Olverembatinib inhibition of Omicron variant-mediated cytokine release [here](#)
- First cases of infection with the 21L/BA.2 Omicron variant in Marseille, France [here](#)

## Guidance and reports

- The World Health Organization published information on Covovax/Nuvaxovid (Novavax) recombinant, adjuvanted COVID-19 vaccine [here](#)

## News and blogs

- Heart-disease risk soars after COVID-19 [here](#)
- Is anti-vaccine sentiment affecting routine childhood immunisations in the UK? [here](#)
- NEJM audio interview on COVID-19 as an endemic disease [here](#)

[Click here](#) to subscribe to the daily evidence digest.

## Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on [COVID-19 transmission](#), SARS-CoV-2 [vaccines](#), and [variants](#) of concern, [post-acute sequelae of COVID-19 \(PASC\)](#), [surgery and COVID-19](#), [rapid testing](#) and [risk mitigation strategies](#).